Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era
Titel:
Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era
Auteur:
Bellmunt, Joaquim Esteban, Emilio del Muro, Xabier García Sepúlveda, Juan Manuel Maroto, Pablo Gallardo, Enrique del Alba, Aranzazu González Etxaniz, Olatz Guix, Marta Larriba, Jose Luis González Arranz, Jose A. Redrado, Miriam Calvo, Alfonso